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The 2009 Revision to the PhRMA Code on
Interactions with Healthcare Professionals:
Challenges and Opportunities for the
Pharmaceutical Industry in the Age of Compliance
HOWARD L. DORFMAN*
INTRODUCTION
The interaction between pharmaceutical manufacturers and
healthcare professionals has been under increased scrutiny for some
period of time. Most of the attention has taken a decidedly negative
view of those interactions with criticism regarding the adverse impact
on the integrity of therapeutic decision making coming from such enti-
ties as Congress, the Office of Inspector General of the Department of
Health and Human Services (the OIG), the Department of Justice, state
attorneys general, and leaders of academic medicine.'
In 2002, the Pharmaceutical Research and Manufacturers of
America (PhRMA) 2 introduced the PhRMA Code on Interactions with
Healthcare Professionals (the 2002 PhRMA Code).' The purpose of
the 2002 PhRMA Code was to reinforce the appropriate nature of the
interaction with healthcare professionals as
professional exchanges designed to benefit patients and to enhance the
practice of medicine. The Code is based on the principle that a health-
care professional's care of patients should be based, and should be
perceived as being based, solely on each patient's medical needs and
the healthcare professional's medical knowledge and experience.*
* Howard L. Dorfman is Counsel in the Life Sciences group at Ropes & Gray LLP
in New York. His practice focuses on FDA regulatory law, fraud and abuse, healthcare
compliance management, and risk management in the pharmaceutical and medical
device industries. An abbreviated version of this article was published in the February
2009 issue of Compliance Today.
1. See Troyen A. Brennan et al., Health Industry Practices that Create Conflicts of
Interest: A Policy Proposal for Academic Medical Centers, 295 JAMA 429 (2006),
available at http://www.ohsu.edu/xd/about/services/integrity/coi/gifts/upload/
Health-Industry-Practices-That-Create-Conflicts-of-Interest.pdf.
2. PhRMA is the trade organization that represents research-based pharmaceutical
and biotechnology companies.
3. PHRMA CODE ON INTERACTIONS WITH HEALTHCARE PROF'LS (2002) (superseded
2009), available at http://www.phrma.org/files/PhRMA%20Code.pdf.
4. Id. at 3.
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Although voluntary, the 2002 PhRMA Code was embraced by
PhRMA members generally and recognized as representing a signifi-
cant shift in marketing practices for an industry that had been pillo-
ried for excessive spending on healthcare professionals without any
patient benefit. In 2003, the 2002 PhRMA Code was designated as a
minimum standard for the pharmaceutical industry's relationships
with health care professionals under the Office of Inspector General
Compliance Program Guidance for Pharmaceutical Manufacturers. 5
Vigilant regarding activities that could be viewed as potentially viola-
tive of the Anti-Kickback statute, the OIG recognized the 2002 PhRMA
Code as a reflection of best practices for the industry, providing "use-
ful and practical advice" for reviewing the industry's relationships with
their customers.6 While stating that following the 2002 PhRMA Code
would not insulate a manufacturer from liability, the OIG did recog-
nize that appropriate conduct would "substantially reduce the risk of
fraud and abuse," and establish the type of record of compliance that
would "help demonstrate a good faith effort to comply with applicable
federal health care program requirements."7 Following the example set
by PhRMA, and responding to the same criticisms expressed by vari-
ous groups, similar ethical guidelines were issued by the medical tech-
nology industry in 2003,8 by the medical imaging equipment
manufacturers in 2004,9 and most recently by the Advanced Medical
Technology Association (AdvaMed), the trade organization represent-
ing medical device manufacturers, in December 2008.10
5. OIG Compliance Program Guidance for Pharmaceutical Manufacturers, 68
Fed. Reg. 23,731 (May 5, 2003), available at http://oig.hhs.gov/authorities/docs/03/
050503FRCPGPharmac.pdf.
6. Id. at 23,737.
7. Id. at 23,737-38.
8. See Kathleen Misovic, AAOS On-Line Service (Dec. 2004), http://www2.aaos.
org/aaos/archives/bulletin/dec04/legal.htm; see also AAOS CODE OF ETHICS &
PROFESSIONALISM FOR ORTHOPAEDIC SURGEONS (2004), available at http://www.aaos.
org/about/papers/ethics/code.asp.
9. NEMA CODE OF ETHICS ON INTERACTIONS WITH HEALTH CARE PROVIDERS (2004),
available at http://www.nema.org/media/pr/upload/NEMA%20CodeofEthics.FAQ.
adopted.pdf.
10. ADVAMED CODE OF ETHICS ON INTERACTIONS WITH HEALTH CARE PROF'LS (2009),
available at http://www.advamed.org/MemberPortal/About/code/ (follow "Code of
Ethics Revised & Restated Download" hyperlink). The revised and expanded Code
tightens the guidance from the original 2005 Code, adds new provisions addressing
industry practices such as royalty arrangements, and establishes a certification
process to foster compliance with the Code. Although sharing many of the guidelines
of the 2009 PhRMA Code revision, the AdvaMed Code addresses certain types of
interactions with healthcare professionals that are more prevalent in the medical
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Yet, notwithstanding the issuance of the various codes addressing
ethical standards in interactions with the healthcare practitioners, criti-
cism of industry conduct as creating an environment where excesses
impacted the healthcare professional's clinical judgment continued.
Troyen Brennan's article characterized the relationship between health-
care practitioners and the pharmaceutical industry as a "conflict of
interest between the physicians' commitment to patient care and the
desire of pharmaceutical companies and their representatives to sell
their products."11 The authors argued for nothing less than a total
ban, or at the very least, severe limits on the providing of any items of
value, no matter how low or de minimis, to physicians out of concern
that bias might be introduced into the prescribing process.
12 Of
greater concern to the industry were congressional hearings and
promises of legislation sharply curtailing pharmaceutical marketing
activities, as well as continuing investigations and prosecutions of vari-
ous pharmaceutical manufacturers for illegal marketing practices that
gave rise to liability for violation of the False Claims Act, among other
federal and state laws.
Thereafter, PhRMA issued a revised code on interactions with
healthcare practitioners in July 2008, which took effect in January
2009 (the 2009 PhRMA Code). 13 While the original 2002 PhRMA
Code represented a significant shift in pharmaceutical industry mar-
keting practices and ended what had been viewed as some of the more
egregious sales and marketing excesses, the 2009 PhRMA Code revi-
sions have been described as more narrowly constructed and represent
a targeted guidance in response to specific criticisms. The revisions
generally reflect current industry "best practices" and take into
account many of the government-imposed changes in marketing
processes that have marked an evolution in the compliance environ-
ment since 2002. Several key changes are being introduced in the
2009 PhRMA Code that will have significant impact on the marketing
and sales practices now in effect for many pharmaceutical manufactur-
ers. Specific areas that are affected by the revisions relate to the pro-
viding of meals by field sales representatives, reminder and practice-
related items, and entertainment of healthcare professionals. Of
greater significance for the members of the pharmaceutical industry is
device industry, such as reimbursement support and providing products free of charge
for evaluation and demonstration purposes.
11. Brennan et al., supra note 1, at 429.
12. Id. at 431-32.
13. PHRMA CODE ON INTERACTIONS WITH HEALTHCARE PROF'LS (2009), available at
http://www.phrma.org/files/PhRMA%20Marketing%2Code% 20 20 0 8 .pdf.
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the fact that compliance with the 2009 PhRMA Code requires a thor-
ough review of internal policies relating to the medical education func-
tion, the retention and payment of consultants and speakers, and the
handling of physician prescribing data within individual companies.
This Article will describe the basic tenets of the 2009 PhRMA
Code, how the 2009 PhRMA Code has been relied upon by at least one
state in crafting its own response to the industry-healthcare profes-
sional debate, and it will conclude with a brief overview of pending
activity apart from the self-policing guidance of the 2009 PhRMA Code
with an outlook on the future of the compliance debate.
I. THE REVISED PHRMA CODE
A. Informational Presentations and Meals
Historically, a standard method by which pharmaceutical com-
pany sales representatives would interact with healthcare professionals
was by providing a meal as a means of facilitating an informational
presentation. The 2002 PhRMA Code permitted manufacturers to
offer healthcare professionals the occasional modest meal solely to
facilitate a presentation or discussion with industry representatives
and others speaking on behalf of the company, but only where the
venue was conducive to informational communication. 14 There was
no other limitation as to location.
The revised, 2009 PhRMA Code allows the modest meal while
making a scientific or clinical information presentation to healthcare
professionals and their staff.15 However, that modest and occasional
meal "offered in connection with informational presentations made by
field sales representatives or their immediate managers should also be
limited to in-office or in-hospital settings.'' 16 It does not eliminate the
out-of-office or out-of-hospital meal entirely as a means of facilitating a
speaker program.
Reading the remainder of the 2009 PhRMA Code and the accom-
panying question and answer section provides clarification regarding
distinctions between the types of pharmaceutical employees in the
context of permitted or prohibited activities. For example, Question
12 indicates that if the pharmaceutical company personnel hosting a
business discussion are home-office based and not field sales, an out-
14. PHRMA CODE ON INTERACTIONS WITH HEALTHCARE PROF'LS 7 (2002) (superseded
2009), available at http://www.phrma.org/files/PhRMA%20Code.pdf.
15. PHRMA CODE ON INTERACTIONS WTH HEALTHCARE PROF'LS 4 (2009).
16. Id.
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of-office or hospital setting for the meal is permitted.17 The explana-
tion does not specifically address non-sales field personnel-such as
Medical Science Liaisons or similar field based medical staff-which,
presumably, would be permitted to provide out-of-office meals.18 By
refusing to utilize the more descriptive language used in other sections
of the 2009 PhRMA Code,19 it is reasonable to conclude that the draft-
ers created certain distinctions as to appropriate conduct based on the
company roles played by pharmaceutical manufacturer personnel.
B. Prohibition on Entertainment and Recreation
The 2002 PhRMA Code permitted entertainment in the context of
consultant meetings or speaker training sessions, provided that such
entertainment and recreation were clearly subordinate both in time
and emphasis to the business agenda of the meeting.20 The 2009
PhRMA Code eliminates entertainment entirely in these contexts.2 '
For the first time, companies are prohibited from providing entertain-
ment or recreation from any interactions with healthcare professionals.
The prohibition applies regardless of the relative value of the activity or
whether it is secondary to the consultant or educational purpose of the
meeting.22
C. Support for Continuing Medical Education
The importance of defining the appropriate role for the pharma-
ceutical industry in relation to support for Continuing Medical Educa-
tion (CME) is reflected in the 2009 PhRMA Code. Unlike the 2002
PhRMA Code, the CME section is now independent of other code pro-
visions. New requirements are consistent with several of the recom-
mendations found in the OIG Compliance Guidelines for
Pharmaceutical Manufacturers and reflect guidelines issued by the
Accreditation Council for Continuing Medical Education (ACCME).
The CME provisions track the general philosophy found through-
out the 2009 PhRMA Code in stressing the need for the industry to
17. Id. at 23.
18. Id.
19. Examples of such descriptive language found in other places in the 2009
PhRMA Code include phrases such as "company representatives," "industry
representatives," and all company "representatives who visit healthcare professionals."
Id. at 4, 14.
20. PHRMA CODE ON INTERACTIONS WITH HEALTHCARE PROF'LS 11 (2002)
(superseded 2009), available at http://www.phrma.org/files/PhRMA°/20Code.pdf.
21. PHRMA CODE ON INTERACTIONS WITH HEALTHCARE PROF'LS 13 (2009).
22. Id. at 5.
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distance the sales and marketing functions from purely educational
endeavors, critical to the independence of developers of CME materi-
als. As the 2009 PhRMA Code suggests, support for CME is intended
to educate healthcare professionals on a full range of treatment
options, not as a means of promoting a particular therapeutic option.23
To accomplish this goal, pharmaceutical companies are to separate the
CME grant review process from involvement of sales and marketing
personnel and to follow ACCME or other accrediting entity stan-
dards.24 Companies are no longer permitted, as they were under the
2002 PhRMA Code, to provide meals or receptions directly at CME
events.25 Instead, companies are allowed to provide funding to the
CME provider for meals to all attendees.26
A significant change in the Code relates to the ability of a pharma-
ceutical manufacturer to provide guidance to the CME provider in the
development of CME programs. The 2009 PhRMA Code states that
manufacturers are no longer permitted to provide guidance regarding
potential speakers or content even if an unsolicited request is received
from the CME provider. 27 These guidelines, which speak of near abso-
lute separation between industry and CME providers, would likewise
suggest that the practice of allowing company medical personnel to
review CME materials in advance for factual accuracy is now highly
suspect, notwithstanding the potential impact on product liability
exposure for those companies that have provided support for a CME
program that is thereafter alleged to have provided inaccurate informa-
tion regarding the sponsor's drug. However, it appears that a company
may establish a Request for Proposals concept as part of the decision
making process regarding which CME areas to fund.28
D. Consultants
The "Consultants" Section of the 2009 PhRMA Code begins by
reiterating the general principles stated in the 2002 PhRMA Code. It
proceeds by enunciating the very basic standards for establishment of
consulting arrangements between manufacturers and healthcare pro-
fessionals and then lists factors that support the existence of bona fide
consultant engagements. 29 A justification is now included-"use [of
23. Id. at 6.
24. Id.
25. Id. at 28.
26. Id.
27. Id.
28. Id. at 29.
29. Id. at 7-9.
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expert] advice . . . to ensure that ... medicines . . . are meeting the
needs of patients"30 -which reprises a consistent theme relating to
patient interests that is stressed throughout the revised code. The
2009 PhRMA Code also contains several additional details regarding
the consultant arrangement, such as the existence of a written contract
and the identification of a need for the services to be provided. The
company should likewise be prepared to justify the need for the num-
ber of consultants being retained. 31
Expanding the criteria to be utilized in the selection of consul-
tants, the 2009 PhRMA Code states that the decision regarding the
selection or retention of healthcare professionals as consultants should
be based on "defined criteria such as general medical expertise and
reputation" and paid based on an undefined "fair market value."
32
Additionally, resorts are expressly deemed inappropriate locations for
consultant meetings.33
The 2009 PhRMA Code suggests new responsibilities for the phar-
maceutical manufacturers regarding the use of consultants apart from
the now common concern regarding appropriate recompense and
venues. The language as to "selection or retention" in the Code sug-
gests a need to monitor consultants and document the extent to which
their services will be required beyond the term fixed by contract. 34 As
will be discussed further, the need to maintain records of payments to
consultant healthcare professionals is not only implicitly suggested by
the 2009 PhRMA Code but required in an increasing number of states.
E. Speaker Programs and Speaker Training Meetings
The concept of the speaker bureau-the retention and training of
healthcare providers to speak at various venues on behalf of a pharma-
ceutical company's products within label-has come under scrutiny
and criticism from various sources for a wide range of reasons. These
reasons include: the excessive payments made to the speakers as a
reward for past prescribing activity or as an inducement for future pre-
scribing, 35 and the possibility of disseminating off-label information
30. Id. at 7.
31. Id. at 8-9.
32. Id. at 7-8.
33. Id. at 8.
34. Id. at 7.
35. Excessive payments made to speakers could be a violation of the Anti-Kickback
statute.
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under the guise of an in-label presentation.36 While the 2009 PhRMA
Code allows for the retention of a healthcare professional as a paid
speaker, speaker programs are afforded separate discussion from con-
sultant activities.37 New restrictions are imposed by the 2009 PhRMA
Code that will require careful review of existing internal policies and
procedures.
The revisions found in the 2009 PhRMA Code incorporate addi-
tional compliance concepts regarding the retaining and training of
speakers that have become ubiquitous in most company compliance
programs since the release of the 2002 PhRMA Code. These additional
compliance concepts reflect the OIG Guidance as well as a number of
Corporate Integrity Agreements (CIA). The 2009 PhRMA Code con-
firms that speaker programs are promotional in nature, and that com-
panies should take care to establish a distinction between such
engagements and CME activities.38 To assist in clarifying the distinc-
tion between such speaking engagements and CME activities, the Code
repeats a number of the requirements suggested for consultant engage-
ments, and requires the establishment of a need for the speaker's ser-
vices and the relevant expertise of the speaker. By way of example,
and specifically responding to the concerns raised, the 2009 PhRMA
Code specifies that any healthcare professional engaged to undertake
external promotional activities is deemed a speaker who should clearly
identify that they are speaking on behalf of the manufacturer and that
the information they present is consistent with current labeling and
applicable FDA guidance. 39
In addition to the responsibilities on the speakers, new require-
ments are imposed on the retaining companies, several of which will
no doubt require a careful review of existing compliance policies and
procedures. Pharmaceutical manufacturers must develop and imple-
ment policies that address the appropriate use of speakers and estab-
lish the appropriate number of speaking engagements for any
particular speaker over time.4 ° Speakers must undergo training
regarding the company's products to understand the approved product
labeling and FDA regulatory requirements.
Of particular note are two new requirements. The pharmaceutical
company is responsible for the active monitoring of its speaker pro-
36. Such a situation could violate the Federal False Claims Act and the Federal
Food, Drug and Cosmetic Act.
37. PHRMA CODE ON INTEACIONS WITH HEALTHCARE PROF'LS 9 (2009).
38. Id. at 10.
39. Id. at 9.
40. Id. at 10.
368 [Vol. 31:361
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grams to verify compliance with all applicable FDA regulations. 4' In
addition, each manufacturer is encouraged to "cap the total amount of
annual compensation it will pay to an individual healthcare profes-
sional in connection with all speaking engagements. 42 No fixed cap
amount is provided by the 2009 PhRMA Code, leaving the decision
regarding establishing a reasonable limit to the judgment of the com-
pany. However, timely access to the pertinent information throughout
the organization to permit an accurate assessment of compensation
paid to any particular speaker may provide challenges for some
companies.
The significance of the revision in the 2009 PhRMA Code regard-
ing the need to actively monitor speaker compliance with FDA regula-
tions cannot be overstated as it relates to the ongoing debate regarding
the proper role of a pharmaceutical company in the dissemination of
truthful and non-misleading medical information to healthcare profes-
sionals. The OIG and various state attorneys general have aggressively
investigated pharmaceutical industry marketing practices for activities
that they believe constitute promotion of products beyond the scope of
the FDA-approved labeling. If such "off label" promotion is suspected,
prosecution for violation of the Food, Drug and Cosmetic Act, as well
as of both federal and state False Claims Acts, have been maintained.
This provision of the 2009 PhRMA Code suggests an attempt to proac-
tively address this issue as relating to presentations by members of a
company's speaker bureau to be sure speakers are responding to unso-
licited inquiries for medical information outside approved labeling
appropriately.43
41. Id.
42. Id.
43. On Monday, January 12, 2009, the U.S. Food and Drug Administration (FDA)
made available a final guidance on industry dissemination of medical or scientific
journal articles and referenced publications that discuss unapproved uses-or "off-
label" uses-of FDA-approved or cleared drugs, biologics, and medical devices. The
long-awaited final guidance recognizes the public health and policy justification
supporting the dissemination of truthful and non-misleading information on off-label
uses. The final guidance permits manufacturers, including their sales representatives,
to disseminate off-label information about their products if such information is in the
form of appropriate (e.g., peer-reviewed and unedited) medical journal articles. See
Matthew Arnold, FDA OKs Distribution of Journal Articles on Off-Label Uses, MED.
MARKETING & MEDIA, Jan. 12, 2009, http://www.mmm-online.com/FDA-OKs-
distribution-of-journal-articles-on-off-label-uses/article/123914/.
369
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F. Prohibition of Non-Educational and Practice Related Items
The 2009 PhRMA Code effectively eliminates the category of
"practice-related gifts" of nominal value imprinted with the company's
name or logo as appropriate for distribution to healthcare profession-
als and their staff.4 4 This includes such classic giveaway items as pens,
mugs, notepads, or other such reminder pieces.45 Instead, the 2009
PhRMA Code redefines "educational items" that are permissible as
"items designed primarily for the education of patients or healthcare
professionals if the items are not of substantial value ($100 or less)
and do not have value to the healthcare professional outside of his or
her professional responsibilities. ' 46 This revision keeps in line with
the stated 2009 PhRMA Code's objective of establishing the industry-
healthcare practitioner relationship as based on education to the physi-
cian and benefit to the patient. Permissible items, however, must be
offered only on an occasional basis and be permitted by law.47 Pens
and mugs and similar pieces do not "advance disease or treatment edu-
cation," and therefore they are banished from the marketing
armamentarium.
48
These newly articulated restrictions do not appear to require that
a gift provided to a healthcare professional have no independent value,
only that the item have no independent value to the healthcare profes-
sional outside of the professional's practice. Similarly, it does not
appear that the prohibition on "practice related items" means that an
educational item cannot have value to the healthcare professional's
practice. Such an interpretation runs counter to other sections of the
2009 PhRMA Code.49 Therefore, items that have value in relation to a
medical practice, such as an anatomical model or a patient tracking
form, are clearly permissible and specifically addressed in the 2009
PhRMA Code as educational items with no value to the healthcare
practitioner outside of the practice and do not represent prohibited
"practice related items."
G. Prescriber Data
Another long-standing and recurring criticism of the pharmaceu-
tical industry is addressed in the 2009 PhRMA Code's section pertain-
ing to the access by companies of data relating to prescribing activities
44. PHRMA CODE ON INTERACTIONS WITH HEALTHCARE PROF'LS 11 (2009).
45. Id.
46. Id. at 12.
47. Id.
48. Id. at 18.
49. See generally id.
370 [Vol. 31:361
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of healthcare professionals. Criticism of access to and use of health-
care practitioner prescribing data by pharmaceutical companies, par-
ticularly by their field-based sales force, had grown since the 2002
PhRMA Code was released without any reference to this issue.5 0 The
2009 PhRMA Code advises companies to use non-patient identifiable
prescribing data responsibly and further requires the development of
company policies regarding the appropriate use of such data.
5
' Com-
panies are further urged to respect and abide by the wishes of any
healthcare professional who requests an opportunity to opt-out of any
process that provides his or her data to sales representatives; to edu-
cate company "employees and agents" regarding company policies;
and to establish disciplinary procedures for misuse of such data.
52
Once again, the 2009 PhRMA Code is responding to an ongoing
source of criticism of the pharmaceutical industry. Beginning in the
early 1990s, electronic records of prescription activity from retail phar-
macies and related sources were linked with physician prescribing
information and sold to pharmaceutical manufacturers. This practice
soon came under fire from a number of physicians, particularly when
healthcare professionals were confronted by sales representatives with
knowledge of their exact prescribing habits .5  The 2009 PhRMA Code
tracks the provisions of the Prescribing Data Restriction Program (the
PDRP)5 4 adopted by the American Medical Association in 2006. The
PDRP formalized the process for allowing physicians to restrict pre-
scribing information from release to pharmaceutical company repre-
sentatives, established an "opt-out" mechanism, and limited access of
sales personnel (including managers) to specific data.5 5 The data in
question includes prescription counts and volume, "change indica-
tors," and other non-physician specific information.
The 2009 PhRMA Code was too late to forestall state action. On
June 30, 2006, the New Hampshire legislature unanimously passed the
Prescription Confidentiality Act, which effectively prohibited the trans-
50. PHRMA CODE ON INTERACTIONS WITH HEALTHCARE PROF'LS (2002) (superseded
2009), available at http://www.phrma.org/files/PhRMA%20Code.pdf.
51. PHRMA CODE ON INTERACTIONS WITH HEALTHCARE PROF'LS 13 (2009).
52. Id.
53. Stephanie Saul, Doctors Object to Gathering of Drug Data, N.Y. TIMES, May 4,
2006, available at http://www.nytimes.com/2006/05/04/business/O4prescribe.html.
See also Robert Steinbrook, For Sale: Physicians' Prescribing Data, 354 NEW ENG. J.
MED. 2745 (2006), available at http://content.nejm.org/cgi/content/full/354/ 2 6 /
2745.
54. AM. MED. AsS'N, PDRP: THE CHOICE IS YOURS, available at http://www.ama-
assn.org/amal/pub/upload/mm/432/pdrp-brochure.pdf (last visited Mar. 21, 2009).
55. Id.
11
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fer of patient or provider identifiable data for most commercial pur-
poses, specifically barring the use of prescriber identifiable data for
detailing purposes.5 6 The legislature cited privacy concerns on the
part of physicians and patients, as well as the opinion that physicians
who are detailed by company representatives tend to prescribe innova-
tor (and therefore more costly than generic drugs), thereby increasing
the state's prescription reimbursement costs. Data miners such as IMS
filed suit in federal court in 2007 challenging the state law on various
grounds, particularly claiming the law violated their First Amendment
right to commercial free speech.5 7 While the district court struck
down the law under the three-part Central Hudson test,5 8 the Court of
Appeals for the First Circuit upheld the New Hampshire law. 59
Other jurisdictions, including Vermont and Maine, have passed
legislation similar to the New Hampshire statute.6 ° While it is prema-
ture to opine as to the eventual outcome of these various state initia-
tives, it is -clear that pharmaceutical companies must be cautious in
implementing internal policies that relate in any way to the use by mar-
keting and sales functions of such data. In addition, in light of obliga-
tions imposed by jurisdictions such as Massachusetts that appear to
exceed those contained in the 2009 PhRMA Code,61 it would be pru-
dent for companies to develop processes for removing identifiable pre-
scriber data from various in-house commercial applications beyond
sales representative access.
H. Training and Conduct of Field Representatives
When pharmaceutical company personnel interact with health-
care professionals concerning medical and scientific issues, the "high-
est ethical standards" should be followed.62 To further reinforce this
concept, companies are required to ensure that all company represent-
atives who visit healthcare professionals (i.e., beyond field-based sales
representatives) receive training on the applicable laws, FDA regula-
tions, and industry codes of practice (i.e., the PhRMA Code), as well as
56. N.H. REV. STAT. ANN. § 318:47-f (2006).
57. IMS Health Inc. v. Ayotte, 490 F. Supp. 2d 163, 165 (D.N.H. 2007), rev'd, 550
F.3d 42 (1st Cir. 2008).
58. Id. at 176 (discussing Central Hudson Gas & Electric Corp. v. New York, 447
U.S. 557 (1980), and its application to IMS Health).
59. IMS Health Inc. v. Ayotte, 550 F.3d 42, 45 (1st Cir. 2008).
60. See ME. REV. STAT. ANN. tit. 22, §§ 1711-E, 8713 (2008); VT. STAT. ANN. tit. 18,
§ 4631 (2008).
61. See infra notes 72-76 and accompanying text.
62. PHRMA CODE ON INTERACTIONS WITH HEALTHCARE PROF'LS (2009), available at
http://www.phrma.org/files/PhRMA%20Marketing%2OCode%202008.pdf.
372 [Vol. 31:361
12
Campbell Law Review, Vol. 31, Iss. 2 [2009], Art. 5
http://scholarship.law.campbell.edu/clr/vol31/iss2/5
2009] OPPORTUNITIES FOR THE PHARMACEUTICAL INDUSTRY 373
training on general scientific and product specific information.63
More importantly, companies are to assess their representatives peri-
odically to determine that they comply with relevant company policies
and take appropriate disciplinary action when representatives fail to
comply.
6 4
Field-based pharmaceutical sales representatives will have oppor-
tunities to utilize their training. Presumably, it will be the responsibil-
ity of these representatives to monitor speaker programs to establish
compliance with the requirements of discussing current, on-label pro-
motional information. The importance of this function should not be
underestimated, particularly given the focus of such entities as the
FDA, the OIG, the Department of Justice, and the various state attor-
neys general in investigating off-label promotion for future prosecution
on both the state and federal level.
I. Formulary Committee Members
An example of how the 2009 PhRMA Code responded to criticism
of the pharmaceutical sales industry since the adoption of the 2002
PhRMA Code can be seen in the newly introduced section on the need
for corporate disclosure relative to interactions with formulary com-
mittee members. While the 2002 PhRMA Code is silent regarding the
issue of disclosure by healthcare professionals of relationships with
industry, the 2009 PhRMA Code states that companies should require
healthcare professionals who consult or speak for industry and sit on
formulary committees to disclose the existence and nature of their
relationship with the company.65 In this regard, the disclosure require-
ments should extend for a minimum of two years following the termi-
nation of the relationship with the company.6 6 However, only if the
formulary committee procedures require it would the company-
retained members recuse themselves from decisions the committee
makes relating to a medicine for which they speak or consult.
II. IMPLEMENTING AND ADHERENCE TO THE CODE
The 2009 PhRMA Code, like its predecessor, is an articulation of
guidance for its members. Antitrust principles prevent an association
such as PhRMA from dictating internal policies to its members. Yet, to
address the criticisms of the industry, as well as take into account the
63. Id. at 14.
64. Id.
65. Id. at 31.
66. Id.
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conduct that gave rise to the several investigations, settlements, and
CIAs since 2002, the 2009 PhRMA Code anticipates a certification pro-
cess for companies to commit to following the provisions by the post-
ing of company "certifications" that policies and processes are in place
to foster Code compliance.67 Further, companies will be encouraged
to seek external verification at least once every three years that they, in
fact, have such policies and processes in place.68
A. Potential Impact on the Pharmaceutical Industry: Opportunities
and Challenges
The PhRMA activities during the past six years that gave rise to the
2002 PhRMA Code and the 2009 PhRMA Code were certainly not
undertaken in a vacuum. Both reflect the state of an industry facing
significant criticism and the development of a response to that
criticism.
The importance of the 2009 PhRMA Code can be seen by virtue of
its being viewed as the most definitive articulation of minimum con-
duct by which individual members of the pharmaceutical industry will
be measured and often judged. We have already noted that the GIG,
for example, viewed the 2002 PhRMA Code as a minimum code of
conduct for pharmaceutical companies that, while not insulating a
manufacturer from liability as a matter of law, would still "substan-
tially reduce the risk of fraud and abuse" and "demonstrate a good
faith effort to comply with applicable federal health care program
requirements.''" We can anticipate a similar articulation of GIG opin-
ion with regard to the 2009 PhRMA Code. However, it is important to
note there has been increased GIG activity during the six years follow-
ing release by PhRMA of the 2002 Code. The increased requirements
of the 2009 PhRMA Code bring potential for increased exposure and
potential liability for any failure to commit the necessary resources in
the review of existing compliance policies and procedures and the
development of new ones as required.
The 2009 PhRMA Code is considered by various states to be an
important basis for determining appropriate industry conduct as new
regulations are adopted that govern interactions between pharmaceuti-
cal companies and healthcare providers on the state level. For exam-
ple, California Health and Safety Code 119402 states that every
67. Id. at 14.
68. Id. at 15.
69. GIG Compliance Program Guidance for Pharmaceutical Manufacturers, 68
Fed. Reg. 23,731, 23,737 (May 5, 2003), available at http://oig.hhs.gov/authorities/
docs/03/050503FRCPGPharmac.pdf.
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pharmaceutical company must adopt a "comprehensive compliance
program" that includes policies that are compliant with the PhRMA
Code and requires conforming changes within six months of any
update or revision of the PhRMA Code. 70 Nevada has likewise adopted
regulations that require pharmaceutical and medical device manufac-
turers to adopt a written marketing code of conduct where adoption of
the most recent version of the PhRMA Code would satisfy the Nevada
requirements.7 1
Another recent state action in this regard took place on August 10,
2008 when Governor Patrick of Massachusetts signed Senate Bill
2863, "An Act to Promote Cost Containment, Transparency and Effi-
ciency in the Delivery of Quality Health Care."' 72 As seen in California
and Nevada, attention is paid to the guidance offered in the PhRMA
Code, as the Massachusetts law requires the Department of Public
Health to promulgate regulations that are "no less restrictive" than
those contained in the most recent version of the PhRMA Code.73
Under the Massachusetts statute, effective January 1, 2009, both phar-
maceutical and medical device manufacturers selling or marketing in
the state have to comply with the Massachusetts Department of Public
Health (the DPH) Code of Conduct.7" The DPH released proposed
implementing regulations in December 2008, which included specific
requirements similar to, but in some cases more expansive than, those
in the PhRMA or AdvaMed codes. 75 The state code requires compa-
nies to undertake specific compliance activities (such as training,
auditing, and instituting policies for corrective action) and to publicly
disclose any payments to HCPs with a value of fifty dollars or more in
connection with sales and marketing activities.76
The Massachusetts legislation has as much in common with
recent OIG enforcement actions as it does with the pharmaceutical and
medical device industry codes, and many requirements will look famil-
iar to those companies operating under corporate integrity agree-
ments. For example, in addition to adopting training programs,
70. CAL. HEALTH & SAFETY CODE § 119402 (West 2006).
71. NEV. REV. STAT. § 639.570 (2008).
72. S. 2863, 2008 Leg. (Mass. 2008).
73. MASS. ANN. LAWS ch. 111N, § 2 (LexisNexis Supp. 2009).
74. Id.
75. Press Release, Mass. Dep't of Pub. Health, Massachusetts Proposes Sweeping
New Rules Governing Sales and Marketing Tactics of Pharmaceutical and Medical
Device Companies (Dec. 10, 2008), available at http://www.mass.gov/?pagelD=eohhs
2pressrelease&L = 1 &LO=Home&sid=Eeohhs2&b=pressrelease&f=081210_newregs&
csid=Eeohhs2.
76. MASS. GEN. LAWS ch. 111N, § 2.
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companies are required to conduct annual audits to monitor company
compliance and to adopt policies and procedures for investigating
instances of noncompliance and reporting such noncompliance to the
state authorities.77 Companies are expected to identify a compliance
officer responsible for monitoring activities relating to the DPH Code,
certify that it has conducted its annual audit and that all activities are
in compliance, and submit a disclosure report annually regarding pay-
ments for marketing expenditures for the prior year.78
B. Industry Oversight Outside the Code
The release of the 2009 PhRMA Code does not represent the final
statement regarding establishing the appropriate level of interaction
between the pharmaceutical industry and healthcare professionals. In
addition to legislative initiatives in other states,7 9 the federal govern-
ment is entering the field.
On January 22, 2009, the Physician Payment Sunshine Act of
2009 (the Sunshine Act) was introduced in the United States Senate by
Senators Charles Grassley (R-IA) and Herb Kohl (D-WI).8 ° The stated
purpose of the Sunshine Act is to "provide for transparency in the rela-
tionship between physicians and manufacturers of drugs, devices, bio-
logicals, or medical supplies for which payment is made under
Medicare, Medicaid, or SCHIP." s Under the bill, these manufacturers
would need to publicly disclose payments and gifts made to HCPs in
excess of $100 with penalties for non-compliance running as high as
$1 million.8 2 A previous version of the Sunshine Act introduced by
Senator Grassley in 2007 had set the disclosure reporting requirement
at $500.83
77. Id.
78. Id. Certain payments in cash or providing items of value, albeit made to HCPs,
are explicitly excluded from the Massachusetts legislation. Such items of value can
include: price concessions made in the normal course of business and documented
appropriately as per the OIG Safe Harbor; the provision of reimbursement
information, unless provided to induce use of a company's products; and drugs or
other support provided through established Patient Assistance Programs that comply
with federal anti-kickback statutes.
79. Seven jurisdictions in addition to Massachusetts have state laws that govern
activities relative to the marketing of pharmaceuticals, medical devices, or both. As of
January 2009, they were California, Maine, Minnesota, Nevada, Vermont, West
Virginia, and the District of Columbia.
80. Physician Payment Sunshine Act of 2009, S. 301, 111th Cong.
81. Id.
82. Id.
83. Physician Payments Sunshine Act of 2007, S. 2029, 110th Cong.
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In fact, several pharmaceutical companies, having already been
subject to exhaustive investigations by federal and state governmental
agencies, have already agreed to list payments made to physicians on a
public web site, most notably Pfizer 4 and Eli Lilly."5 Given the cur-
rent environment in Congress regarding the relative cost of reimburs-
ing pharmaceuticals under the present reimbursement systems, and
the belief that such costs are increased as a result of inappropriate rela-
tionships between industry and the HCPs, it is highly likely the bill
will pass.
CONCLUSION
The implications of the 2009 PhRMA Code for the U.S. pharma-
ceutical industry are significant. We have already noted how the 2009
PhRMA Code will be considered the minimum standard of conduct by
the OIG and by the various states. In this regard, it is critical for the
individual companies to review their existing policies and procedures
to determine if they meet the new requirements suggested by the
revised Code. Even those entities currently operating under a CIA,
deferred prosecution, or other compliance-related obligations would
need to determine the extent to which the 2009 PhRMA Code requires
processes such as external verification. Moreover, as PhRMA has indi-
cated it will direct any complaints as to inappropriate corporate con-
duct to that company's Chief Compliance Officer (CCO) and will
identify on its website those companies that have obtained external
verification of its policies and procedures to foster compliance, new
grounds for criminal and civil liability may develop. It is safe to state
that compliance has become a complex and ongoing issue for the phar-
maceutical industry that will continue to dominate the industry's
already crowded agenda for years to come.
84. Pfizer to Publicly Disclose Payments to U.S. Physicians, Healthcare Professionals
and Clinical Investigators, MED. NEws TODAY, Feb. 11, 2009, http://www.medicalnews
today.com/articles/ 138525.php.
85. Posting of Jacob Goldstein to WSJ Health Blog, http://blogs.wsj.com/health/
2008/09/24/eli-lilly-to-disclose-payments-to-doctors/ (Sept. 24, 2008, 9:06 EST).
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